If you've been looking into weight loss options lately, you've probably come across one name again and again: semaglutide. It's been called a major shift, a breakthrough, even a highly effective medication. But what actually is it? And could it be right for you?
Let's start with the basics.
What Is Semaglutide?
Semaglutide is the active ingredient in several FDA-approved medications, including Wegovy (for weight loss) and Ozempic (for type 2 diabetes). It belongs to a class of medications called GLP-1 receptor agonists, drugs that mimic a natural hormone your body already produces.
Think of it this way: your body naturally produces a hormone called GLP-1 that tells your brain, "I'm full, stop eating." But for many people, this natural signal isn't strong enough to maintain a healthy weight. Semaglutide amplifies that signal, making it more powerful and longer-lasting.
Key Facts at a Glance
- Drug class: GLP-1 receptor agonist
- How it's taken: Once-weekly injection; a daily tablet form is also FDA-approved
- FDA approved for: Weight management (Wegovy) and type 2 diabetes (Ozempic)
- Clinical evidence: studied in the STEP trial program over 68 weeks (NEJM 2021); the result figures are in the publication and describe the approved product
- FDA-approved forms: Wegovy and Ozempic, both manufactured by Novo Nordisk. Compounded semaglutide is a separate category, prepared by a state-licensed compounding pharmacy against an individual prescription and not FDA-approved as a final product, so trial figures from the approved products do not carry over to it
How Does Semaglutide Work?
Semaglutide works through three main mechanisms that make weight loss feel less like a battle and more like a natural process your body supports.
1. Appetite Suppression at the Brain Level
Semaglutide activates GLP-1 receptors in areas of the brain involved in appetite regulation. This reduces the intensity of hunger signals, making it easier to eat less without feeling deprived.
Many patients describe this as "food noise" disappearing. The constant thoughts about what to eat next, the cravings, the mental chatter, it quiets down significantly.
2. Slower Digestion
The medication signals your stomach to empty more slowly. This means food stays in your stomach longer, and you feel full and satisfied for longer after eating. Smaller portions suddenly feel like enough.
3. Better Blood Sugar Control
Semaglutide helps your pancreas release insulin more effectively when your blood sugar rises.
Who Is Semaglutide For?
Semaglutide is approved for adults who meet specific clinical criteria. You may be a candidate if you have:
- A BMI of 30 or higher (classified as obesity)
- A BMI of 27 or higher with at least one weight-related health condition (type 2 diabetes, high blood pressure, high cholesterol, sleep apnea)
Your doctor will also consider your overall health history, current medications, and any medical conditions.
What Results Can You Expect?
The landmark STEP (Semaglutide Treatment Effect in People with Obesity) clinical trials provide the most reliable data:
- STEP 1: Established clinically meaningful average reduction against placebo over 68 weeks in adults with overweight or obesity.
- STEP 3: When combined with lifestyle intervention, the trial reported a larger average reduction than lifestyle support alone. The figures are in the publication and describe that approved product.
- STEP 5: Followed participants for two years and showed the effect held while treatment continued.
Individual results vary based on genetics, lifestyle, medication adherence, and metabolic health. Results may vary.
How Is Semaglutide Taken?
Semaglutide is a once-weekly injection, administered in the abdomen, thigh, or upper arm using a tiny needle. Treatment follows a gradual dose escalation schedule.
How Treatment Typically Starts
However you pursue treatment, the legitimate path looks the same: a medical assessment of your history and medications, review by a physician licensed in your state, a prescription only if that physician decides treatment is appropriate, dispensing by a state-licensed pharmacy, and ongoing physician access during treatment. Any provider that skips one of those steps is the wrong provider.
This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication. Individual results may vary. Clinical data referenced from the STEP 1 (N Engl J Med 2021), STEP 3 (JAMA 2021) and STEP 5 (Nat Med 2022) trials; see Sources.
Related 2026 guides
Frequently Asked Questions
What does semaglutide do for weight loss?
Semaglutide reduces appetite, slows stomach emptying, and acts on GLP-1 receptors in areas of the brain involved in appetite regulation. Reduced appetite can mean eating smaller portions without consciously trying to; when and how strongly appetite changes vary from person to person. The STEP-1 trial (NEJM 2021) documented that effect over 68 weeks in adults taking an FDA-approved product; the figures are in the publication and describe that product rather than a compounded preparation. In the STEP 1 trial, participants taking semaglutide also showed greater improvement in cardiometabolic risk factors than those taking placebo.
Who is semaglutide for?
Brand-name Wegovy (semaglutide) is FDA-approved for chronic weight management in adults with body mass index 30 or higher, or 27 or higher with at least one weight-related condition (such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea). Ozempic and Rybelsus (also semaglutide) are FDA-approved for type 2 diabetes. A US-licensed physician makes the final eligibility determination based on full medical history, contraindications, and treatment goals.
How long do you take semaglutide?
Current clinical guidance treats obesity as a chronic disease and supports long-term semaglutide use for patients who tolerate it well and continue to benefit. The STEP-1 extension trial showed that patients who stopped semaglutide regained most of their lost weight within one year off medication; the figures are in the publication. What happens after a patient reaches a goal is decided between patient and physician; the STEP 1 extension found that weight tended to return after treatment stopped. The long-term decision is made between patient and physician based on response, side effects, and overall health.
What is the difference between Ozempic, Wegovy, and Rybelsus?
All three contain the same active ingredient: semaglutide. Ozempic is FDA-approved for type 2 diabetes and, per its current prescribing information, comes as a weekly injection and as a daily tablet. Wegovy is FDA-approved for chronic weight management and, per its current prescribing information, comes as a weekly injection and as a daily tablet. Rybelsus is a daily oral tablet FDA-approved for type 2 diabetes, with strict dosing requirements (empty stomach, up to 4 ounces of water, wait 30 minutes before food). All three are manufactured by Novo Nordisk.
How fast does semaglutide work for weight loss?
Individual response varies, and no specific amount or timeline of weight loss is promised. The prescribing clinician sets the dose, monitors progress, and discusses realistic expectations based on the individual medical history. Treating obesity is a long-term undertaking, and the decision to start, continue, or stop treatment belongs to the patient and their clinician.
Sources
This article is based on the following primary sources. Links open the original documents.
- 1.WEGOVY (semaglutide) injection / tablets, Prescribing Information, sections 1, 12.1 and 14.2 · DailyMed, U.S. National Library of Medicine (label by Novo Nordisk) · accessed
- 2.OZEMPIC (semaglutide) injection, Prescribing Information, sections 1 and 12.1 · DailyMed, U.S. National Library of Medicine (label by Novo Nordisk) · accessed
- 3.RYBELSUS and OZEMPIC (oral semaglutide) tablets, Prescribing Information, section 2.1 Important Administration Instructions · DailyMed, U.S. National Library of Medicine (label by Novo Nordisk) · accessed
- 4.Semaglutide Injection: MedlinePlus Drug Information · MedlinePlus, U.S. National Library of Medicine · accessed
- 5.Compounding and the FDA: Questions and Answers · U.S. Food and Drug Administration · accessed
- 6.Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension (Wilding et al., Diabetes Obes Metab 2022; PMID 35441470, PMC9542252) · PubMed Central, U.S. National Library of Medicine · accessed
- 7.Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial (Wadden et al., JAMA 2021; PMID 33625476, PMC7905697) · PubMed Central, U.S. National Library of Medicine · accessed
- 8.Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial (Garvey et al., Nat Med 2022; PMID 36216945, PMC9556320) · PubMed Central, U.S. National Library of Medicine · accessed
- 9.Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1; Wilding et al., N Engl J Med 2021; PMID 33567185) · PubMed, U.S. National Library of Medicine · accessed
Majesta Health articles are written against primary sources (FDA labeling, NIH and CDC publications, state statutes) and each one passes a documented compliance review before publication. Where an article cites external sources, they are listed at the end of that article so you can check them yourself. No article currently carries an individual physician review; when a physician reviews an article, that page will show the reviewer's name, NPI and review date.
- Written against primary sources: FDA labeling and safety communications, NIH and CDC publications, state statutes and medical board rules
- Documented compliance review against FDA, FTC and LegitScript requirements before publication
- External sources, where an article cites them, are listed at the end of that article with links to the original documents
- Compounded medications are described as not FDA-approved as final products on every page that mentions them